Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAsan Medical Center
About this trial
The purpose of this study is to evaluate the incidence, prevalence, clinical characteristics and prognosis of Crohn's disease and ulcerative colitis over time in a district of Seoul, Korea.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Definite cases of CD and UC
clinical history of abdominal pain, weight loss, malaise, diarrhea, and/or rectal bleeding
endoscopic findings of mucosal cobblestoning, linear ulceration, skip areas, or perianal disease
radiologic findings of stricture, fistula, mucosal cobblestoning, or ulceration
Disqualifiers
IBD unclassified
Ethnic groups other than Korean
Trial population
The study is performed in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. The population of the study area was racially and ethnically homogeneous and was relatively stable in number.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
2,000 Participants
are grouped into 1 trial groupGroup A: The Songpa-Kangdong cohort of IBD
Trial outcomes
Primary outcomes
1
Incidence rate and prevalence rate of IBD
1. Annual incidence rate of Crohn's disease and ulcerative colitis 2. Prevalence rate of Crohn's disease and ulcerative colitis as of Dec 31, 2017.
Time frame
1986-2017 (up to 31 years)Secondary outcomes
1
Clinical features of patients with IBD
1. Clinical characteristics of patients newly diagnosed with Crohn's disease or ulcerative colitis: gender, presenting symptoms, duration between symptoms to diagnosis, and phenotypes, etc. 2. Clinical course of patients newly diagnosed with Crohn's disease or ulcerative colitis: development of complications (strictures, perforations), intestinal resection rate, hospitalization rate, mortality, and pregnancies and their outcomes 3. Treatment modalities of IBD and their trends: use of medication (5-ASA, corticosteroids, immunomodulators, and biologic agents, etc.)
Time frame
1986-2017 (up to 31 years)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Asan Medical Center
Lead sponsor
Kyung Hee University Hospital at Gangdong
Collaborator
Seoul National University Hospital
Collaborator
Seoul National University Bundang Hospital
Collaborator
Samsung Medical Center
Collaborator
Konkuk University Medical Center
Collaborator
National Police Hospital
Collaborator
Seoul Veterans Hospital
Collaborator
hansol hospital
Collaborator
Kangdong Seoul Clinic
Collaborator
Jamsil Seoul Surgical Clinic
Collaborator
Song Do Colorectal Hospital
Collaborator
Yang Hospital
Collaborator
Daehang Hospital
Collaborator
Kangdong Sacred Heart Hospital
Collaborator
Source ClinicalTrials.gov